OBJECTIVE: There is growing evidence that circulating soluble receptor for advanced glycation end products (sRAGE) exerts antiatherogenic effects as a decoy receptor that abolishes RAGE signalling. A previous study reported that oxidized low-density lipoprotein (oxLDL) can be one of  the RAGE ligands. The present cross-sectional study investigated the clinical association between sRAGE and oxLDL in humans.METHODS: Serum levels of the conventional atherosclerotic risk factors, sRAGE and malondialdehyde-modified low-density lipoprotein (MDA-LDL) were analysed in asymptomatic  subjects; MDA-LDL was measured as a biomarker of oxLDL.RESULTS: Mean serum levels of sRAGE and MDA-LDL were 1101 ng/l and 57.6 IU/l, respectively, in 33 subjects of mean age 65 years. Simple linear regression analysis showed a significant inverse correlation between sRAGE and  MDA-LDL. Stepwise multiple linear regression analysis confirmed MDA-LDL to be independently, significantly and inversely correlated with sRAGE.CONCLUSIONS: An independent, significant and inverse correlation was shown to exist between circulating levels of sRAGE and oxLDL (MDA-LDL),  which suggests that part of the antiatherosclerotic effects of sRAGE may be related to oxLDL quenching.
Aged Asymptomatic Diseases